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The major histocompatibility complex (MHC) class II-restricted antigen processing pathway
presents antigenic peptides acquired in the endocytic route for the activation of CD4+ T
cells. Multiple cancers express MHC class II, which may influence the anti-tumor immune
response and patient outcome. Low MHC class II expression is associated with poor sur-
vival in diffuse large B-cell lymphoma (DLBCL), the most common form of aggressive
non-Hodgkin lymphoma. Therefore, we investigated whether gamma-interferon-inducible
lysosomal thiol reductase (GILT), an upstream component of the MHC class II-restricted
antigen processing pathway that is not regulated by the transcription factor class II trans-
activator, may be important in DLBCL biology. GILT reduces protein disulfide bonds in the
endocytic compartment, exposing additional epitopes for binding to MHC class II and facil-
itating antigen presentation. In each of four independent gene expression profiling cohorts
with a total of 585 DLBCL patients, low GILT expression was significantly associated with
poor overall survival. In contrast, low expression of a classical MHC class II gene, HLA-DRA,
was associated with poor survival in one of four cohorts.The association of low GILT expres-
sion with poor survival was independent of established clinical and molecular prognostic
factors, the International Prognostic Index and the cell of origin classification, respectively.
Immunohistochemical analysis of GILT expression in 96 DLBCL cases demonstrated vari-
ation in GILT protein expression within tumor cells which correlated strongly with GILT
mRNA expression. These studies identify a novel association between GILT expression
and clinical outcome in lymphoma. Our findings underscore the role of antigen process-
ing in DLBCL and suggest that molecules targeting this pathway warrant investigation as
potential therapeutics.
Keywords: GILT, MHC class II, antigen processing and presentation, diffuse large B cell lymphoma, tumor
immunology
INTRODUCTION
The major histocompatibility complex (MHC) class II-restricted
antigen processing pathway generates cell-surface peptide-MHC
class II complexes essential for the activation of CD4+ T cells
(1). The three classical MHC class II proteins, HLA-DP, HLA-
DQ, and HLA-DR, are heterodimers composed of an α and β
chain encoded by A and B genes, respectively (e.g., HLA-DRA and
HLA-DRB) (2). MHC class II molecules assemble with invari-
ant chain (Ii) in the endoplasmic reticulum. Ii is responsible for
trafficking the class II-Ii complex to the endocytic pathway and
protecting the peptide binding groove from prematurely acquiring
a peptide. Gamma-interferon-inducible lysosomal thiol reductase
(GILT) catalyzes the reduction of protein disulfide bonds in the
late endosomes and lysosomes, thereby exposing buried peptide
epitopes for binding to MHC class II and enhancing the MHC
class II-restricted presentation of a number of epitopes (3–9).
In the lysosomes, proteases degrade endocytosed and endoge-
nous proteins to form class II-binding peptides. A non-classical
MHC class II protein HLA-DM mediates loading MHC class II
with a high affinity peptide. Peptide-MHC class II complexes are
then directed to the cell surface for recognition by and activation
of CD4+ T cells. CD4+ T cells augment anti-tumor immunity,
in part through promoting the differentiation and maintenance
of CD8+ cytotoxic T cells (10–12). MHC class II molecules are
expressed by professional antigen presenting cells (APCs), such as
dendritic cells (DCs) and B cells, as well as cancers derived from
these cell types. In addition, ectopic expression of MHC class II has
been described on multiple cancers, including melanoma, breast,
colon, thyroid, and cervical (6, 13–16). Therefore, MHC class II-
restricted processing and presentation by tumor cells may exert a
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major influence over T cell responses and play a critical role in
anti-tumor immunity.
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of aggressive lymphoid neoplasm, accounting for 30%
of adult non-Hodgkin lymphomas (17). DLBCL is a hetero-
geneous disease with large variations in clinical outcome (17).
Prognostic stratification is based on clinical risk factors used
to determine the International Prognostic Index (IPI), which
incorporates patient age at diagnosis, tumor stage, serum lac-
tate dehydrogenase level, performance status, and number of
extra-nodal sites (18). The combination of cyclophosphamide,
hydroxydaunorubicin (doxorubicin), Oncovin®(vincristine), and
prednisone (CHOP) had been the standard chemotherapy regi-
men for decades. The recent addition of rituximab, a monoclonal
antibody (mAb) to CD20, to the treatment protocol (R-CHOP) has
significantly improved patient survival (19, 20). Gene expression
profiling (GEP) studies have demonstrated molecular heterogene-
ity in histologically similar DLBCL tumors and identified gene
expression signatures which could offer more accurate prognos-
tic stratification compared to the IPI (21–29). Alizadeh et al.
demonstrated distinct molecular subgroups based on the cell of
origin (COO) or differentiation state of the tumor (21). Patients
with germinal center B cell-like (GCB) DLBCL have significantly
improved survival compared to activated B cell-like (ABC) DLBCL
(21). Subsequent GEP studies have identified that the immune
response plays a favorable role in prognosis (22, 27, 28). In
particular, low expression of genes involved in MHC class II-
restricted antigen presentation is associated with poor survival
in DLBCL (22, 27, 30–32).
Gamma-interferon-inducible lysosomal thiol reductase is a key
component of the MHC class II-restricted antigen processing and
presentation pathway. However, unlike other members of this
pathway including HLA-DR, HLA-DP, HLA-DQ, HLA-DM, and
li, GILT is not regulated by transcription factor class II trans-
activator (CIITA) (33–35). Therefore, we sought to determine
whether GILT expression levels may provide further prognostic
value. Although GILT mRNA expression was previously identified
as part of the “host-response signature” in DLBCL by Monti et al.
this study did not observe an association of the “host-response
signature” with survival (26). We hypothesized that low GILT
expression, which is predicted to result in impaired presentation
of a subset of class II-restricted epitopes, would be associated with
poor patient survival. In each of four independent GEP cohorts
with a total of 585 DLBCL patients, low GILT expression was
associated with poor overall survival. GILT was a better predic-
tor of survival than HLA-DRA, a classical MHC class II gene.
GILT expression was independent of the clinical IPI score, and
the association of GILT expression with survival was independent
of COO classification, suggesting that GILT represents an impor-
tant independent aspect of tumor biology. Immunohistochemi-
cal analysis of GILT expression in 96 DLBCL tissue microarray
(TMA) specimens demonstrated that variation in GILT protein
expression within tumor cells correlated with GILT mRNA expres-
sion from the GEP studies. This study demonstrates that GILT
expression levels correlate with clinical outcome and underscore
that the antigen processing pathway is critical to patient survival
in DLBCL.
MATERIALS AND METHODS
PATIENT CHARACTERISTICS AND GEP DATASETS
Using the National Center for Biotechnology Informa-
tion (NCBI) Gene Expression Omnibus (GEO), we identi-
fied three GEP datasets from pre-treatment DLBCL biopsy
specimens that included patient survival data and probes
for quantification of GILT and HLA-DRA mRNA expres-
sion (Lenz: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE10846, Hummel: http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE4475, Shaknovich: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE23501, Table 1). Data regarding overall
survival, follow-up time, IPI, COO classification, and morpho-
logic and molecular diagnosis were collected directly from the
GSE file. The Lenz et al. dataset was divided into two groups based
on treatment regimen (CHOP vs. R-CHOP) (23). The Hummel
et al. dataset contained 220 mature aggressive B-cell lymphomas;
we included all patients who had survival information and the
morphologic diagnosis of DLBCL, but did not have the molecular
diagnosis of Burkitt lymphoma and did not receive rituximab (24).
All patients in the Shaknovich et al. dataset were included in our
analysis (29). Gene probes were identified based on reported plat-
form data. GILT expression was represented by the single probe ID
201422_at. HLA-DRA expression was represented by two probes:
IDs 208894_at and 210982_s_at.
A cut-off point of the 10% of patients with the lowest gene
expression was selected a priori and used to examine the associa-
tion with survival. For GILT, this cut-off point was selected based
on the enzymatic activity of GILT, as a loss of GILT function is only
anticipated with a significant loss or absence of GILT expression.
This concept has been validated in vivo, as we observe a phenotypic
difference between wild-type and GILT knockout mice, but not
between wild-type and GILT heterozygous mice (4). The cut-off
point of 10% was selected for HLA-DRA, because prior assessment
of multiple cut-off points demonstrated that the 10% of patients
with the lowest HLA-DRA gene expression have the highest risk of
death and worst survival in DLBCL and that the hazard ratio (HR)
of death is a smooth, non-linear function of HLA-DRA expression
(27). Therefore, we used the previously determined cut-off point
for HLA-DRA expression in DLBCL survival.
STATISTICAL ANALYSIS
The correlation between two HLA-DRA probes was tested using
the Spearman correlation coefficient. Since this correlation was
statistically significant, the average expression value from the two
probes was used in the analysis. The association between sur-
vival and gene expression was assessed by comparing the sur-
vival for ≤10 vs. >10% GILT and HLA-DRA expression levels.
This cut point was selected based on the rationale as discussed
above. Subsequently, alternative cut-off points (20, 30, and 50%)
were explored. Only the 10% cut-off point led to a statisti-
cally significant relationship between low GILT expression and
poor survival across all four cohorts (data not shown). When
HLA-DRA was assessed with multiple cut-off points, a signifi-
cant relationship between low HLA-DRA and survival was only
observed in the Lenz CHOP cohort (data not shown). Since the
additional cut-off points did not lead to significant results across
the four cohorts as expected, we focused on the presentation of
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Table 1 | Summary of DLBCL GEP cohorts.
Cohort and treatment Lenz CHOP Hummel CHOP Lenz R-CHOP Shaknovich R-CHOP
No. of patients 181 102 233 69
Study group Multinational LLMPP Multinational MMMLNP Multinational LLMPP British Columbia Cancer Agency
End points and covariates OS, IPI, COO OS, COO OS, IPI, COO OS, PFS, IPI, COO
Median age, years (range) 62 (14–88) 65 (8–93) 60 (17–92) 62 (16–92)
IPI score (%)
IPI=0 18/157 (11) N/A 28/164 (17) 0/65 (0)
IPI=1 44/157 (28) 42/164 (26) 12/65 (18)
IPI=2 53/157 (34) 43/164 (26) 21/65 (32)
IPI=3 29/157 (18) 30/164 (18) 19/65 (29)
IPI=4 13/157 (8) 16/164 (10) 13/65 (20)
IPI=5 0/157 (0) 5/164 (3) 0/65 (0)
COO (%)
ABC-like 74/181 (41) 37/102 (36) 93/233 (40) 20/69 (29)
GCB-like 76/181 (42) 38/102 (37) 107/233 (46) 40/69 (58)
Unclassified 31/181 (17) 27/102 (26) 33/233 (14) 9/69 (13)
Primary data source NCBI GSE10846 NCBI GSE4475 NCBI GSE10846 NCBI GSE23501
Measurement platform Affymetrix-HG U133 Plus 2.0 Affymetrix-HG U133A Affymetrix-HG U133 Plus 2.0 Affymetrix-HG U133 Plus 2.0
LLMP, Lymphoma and Leukemia Molecular Profiling Project; MMMLNP, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe,
OS, overall survival; PFS, progression free survival; IPI, international prognostic index; N/A, not available; COO, cell of origin classification; ABC, activated B cell-like;
GCB, germinal center B cell-like; NCBI, National Center of Biotechnology Information; GSE, gene expression omnibus series. The number of patients in each cohort
indicates the total number of patients with DLBCL with OS data. Since the IPI score and COO were not reported for all patients, the n value is decreased in the IPI
and COO analyses. References for the cohorts are (23, 24, 29).
the analysis with the 10% cut-off. The non-parametric Kaplan–
Meier method was used to estimate the overall survival curve
for each group. A Cox proportional hazards model was used to
test the difference in overall survival between the groups using
the p-value from the score test; the HR and its 95% confidence
interval (CI) also were reported. Additional analyses assessed the
association between survival and GILT expression adjusted for
COO using the Cox proportional hazards model. For the asso-
ciation between GILT expression and IPI score, analysis of vari-
ance was employed. A two sample independent t -test was used
to compare GILT expression in GCB and ABC subtypes. The
Spearman correlation coefficient was used to test the correlation
between GILT and HLA-DRA expression, and GILT mRNA and
protein expression. A p-value <0.05 was considered significant.
Analyses were conducted using SAS V9.1.2 software (Cary, NC,
USA).
CELLS AND TISSUES
De-identified formalin-fixed paraffin-embedded tonsil tissue
blocks were obtained from the Research and Development Tissue
Bank at Ventana Medical Systems (Tucson, AZ, USA). Formalin-
fixed paraffin-embedded TMAs were generously provided by Dr.
Wolfram Klapper and the Molecular Mechanisms in Malignant
Lymphomas Network Project (MMMLNP). The human subjects
protocols of the MMMLNP were approved by the ethics commit-
tees of all participating institutions (24). The TMAs contained
47 tumor sections from the Hummel CHOP cohort and an addi-
tional 49 DLBCL specimens from GEO database GSE22470 (36,
37), which were selected by the same criteria as the Hummel CHOP
cohort but did not contain survival data.
IMMUNOHISTOCHEMISTRY
Immunohistochemical staining was performed on a Benchmark
ULTRA instrument (Ventana Medical Systems). Heat-induced
epitope retrieval was performed using Cell Conditioning-1 (Ven-
tana Medical Systems). Sections were blocked using BLOXALL™
endogenous peroxidase and alkaline phosphatase blocking solu-
tion (Vector Laboratories, Burlingame, CA, USA). Sections were
stained with rabbit anti-GILT polyclonal antibody (Catalog#
S1265, 1:3000 dilution, Epitomics, Burlingame, CA, USA) fol-
lowed by the OptiView DAB IHC detection kit, Hematoxylin II
counterstain, and Bluing reagent (Ventana Medical Systems). Uni-
versal negative control serum (BioCare Medical, LLC, Concord,
CA, USA) served as a negative control. DLBCL cell lines OCI-LY3,
which is of the ABC subgroup, and OCI-LY19, which is of the
GCB subgroup, were provided by the Arizona Lymphoid Tissue
and Blood Repository (University of Arizona, Tucson, AZ, USA)
(21, 38).
Staining of the TMA cores was scored with light microscopy by
a board-certified pathologist blinded to data associated with the
specimens. The DLBCL specimens were evaluated for the pre-
dominant tumor cell staining intensity, percent of tumor cells
staining, predominant APC staining intensity, and percent of APCs
present in the tumor. Staining was scored using a scale from 0 to
4 with 0.25 increments based on the intensity of the staining and
the amount of stained vesicles within each cell. The predominant
staining intensity present in the cells of interest was used.
CONFOCAL MICROSCOPY
Lymphoma cell lines were plated on alcian blue-coated coverslips,
fixed with acetone, and permeabilized with methanol. Antibodies
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were diluted in PBS with 0.05% saponin, 10% FBS, 10 mM glycine,
10 mM HEPES pH 7.4, and 0.5% sodium azide. Cells were stained
with rabbit anti-human GILT serum (1:800 dilution; kindly pro-
vided by Dr. Peter Cresswell) and mouse anti-human HLA-DR
mAb (2.5µg/ml, clone G46-6, BD Pharmingen, San Jose, CA,
USA). Secondary antibodies Alexa Fluor 555-conjugated goat
anti-rabbit IgG (H+ L) and Alexa Fluor 488-conjugated goat anti-
mouse IgG (H+ L) (Invitrogen, Carlsbad, CA, USA) were used
at 2.5µg/ml. Nuclei were detected with Hoechst 33342 (1:15,000
dilution; Invitrogen).
RESULTS
VARIATION IN GILT EXPRESSION IN DLBCL AND CUT POINT
DETERMINATION
We identified four DLBCL cohorts (Table 1) to examine the rela-
tionship between GILT expression in DLBCL tumors and overall
patient survival. Figure 1A illustrates the range of GILT mRNA
expression in DLBCL specimens from patients in the four cohorts.
These data show that all cohorts exhibited variation in GILT
expression in DLBCL tumors across patients. The shift in relative
GILT expression in the Hummel et al. cohort is due to a differ-
ence in measurement platform. Boxes depict the 10% of patients
with the lowest GILT expression who were selected to examine
the impact of low GILT expression on overall survival in DLBCL
(Figure 1A).
The cut-off point of the 10% of patients with the lowest GILT
gene expression was selected a priori prior to evaluation of the
datasets. Taking into account that GILT is an enzyme which cat-
alyzes multiple rounds of reactions, a loss in function is only
anticipated in the patients with the lowest levels of gene expres-
sion. Supporting the hypothesis, we have previously reported that
while there is a significant difference in MHC class II-restricted T
cell responses between GILT knockout and wild-type mice, no dif-
ference in phenotype is observed between GILT heterozygous and
wild-type mice (4). Therefore, we utilized the≤10% GILT expres-
sion cut-off point to represent the patients with a significant loss
or absence of GILT.
LOW GILT EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN ALL
DLBCL COHORTS
We compared the Kaplan–Meier survival curves of patients with
≤10 vs. >10% GILT mRNA expression in the pre-treatment
tumor biopsy (Figure 1B). In each cohort, patients with low
GILT expression had significantly shortened overall survival com-
pared to patients with higher GILT expression. In the Lenz CHOP
cohort, the median overall survival of patients with low GILT
expression was 1.1 years compared to 5.4 years with high GILT
expression. In the Hummel CHOP cohort, the median survival
significantly increased from 0.6 years in patients with the low-
est 10% GILT expression to 2.5 years in the remaining patients.
Median survival time could not be determined in the two R-CHOP
cohorts as survival was significantly improved and the major-
ity of patients survived during the follow-up period. Despite the
improved survival in patients treated with rituximab, low GILT
expression remained significantly associated with poor survival in
the Lenz R-CHOP and Shaknovich R-CHOP cohorts (p= 0.014
and p= 0.046, respectively). To further quantify the impact of low
FIGURE 1 | Low GILT gene expression is associated with poor survival
in all DBLCL cohorts. (A) The relative mRNA expression of GILT in each
patient in the four cohorts. Each symbol represents a single patient. The line
and error bars indicate the mean±SEM. The box indicates the 10% of
patients with the lowest GILT expression. (B) Kaplan–Meier survival curves
comparing patients with ≤10 (gray line) vs. >10% GILT gene expression
(black line). The p-values, hazard ratio (HR), and 95% confidence interval (CI)
comparing survival of patients with ≤10 and >10% expression of GILT are
indicated for each cohort. Lenz CHOP: n=18≤10% GILT, n=163>10%
GILT, Hummel CHOP: n=10≤10% GILT, n= 92>10% GILT, Lenz R-CHOP:
n=23≤10% GILT, n=210>10% GILT, Shaknovich R-CHOP: n= 7≤10%
GILT, n= 62>10% GILT.
GILT expression on survival in DLBCL, the HR and 95% CIs were
determined for all cohorts comparing the 10% of patients with
the lowest GILT expression with the remaining 90% of patients
(Figure 1B). Patients with low GILT expression had a 2.1–3.7
times greater risk of death compared to patients with higher
GILT expression. These data show that patients with low GILT
expression in the DLBCL tumor have significantly poorer overall
survival.
LOW HLA-DRA EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN
ONE OF FOUR COHORTS
Next, we compared the association of low GILT gene expression
with poor survival to the impact of low expression of a representa-
tive MHC class II gene HLA-DRA. Low HLA-DR gene and protein
expression have previously been shown to be associated with poor
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survival (22, 27, 30–32, 39–41). Prior studies have demonstrated
that the HR of death in DLBCL is a smooth, non-linear function of
HLA-DRA expression and that the 10% of patients with the lowest
HLA-DRA gene expression have the highest risk of death and worst
survival (27). Therefore, we used this established cut-off point to
evaluate the effect of HLA-DRA expression on DLBCL survival in
the four cohorts. Figure 2A demonstrates the range in HLA-DRA
FIGURE 2 | Low HLA-DRA gene expression is associated with poor
survival in one of four DBLCL cohorts. (A) The relative mRNA expression
of HLA-DRA in each patient in the four cohorts. Each symbol represents a
single patient. The line and error bars indicate the mean±SEM. The box
indicates the 10% of patients with the lowest HLA-DRA expression. The
closed, black symbols denote the 10% of patients with the lowest GILT
expression shown in the boxes in Figure 1A. (B) Kaplan–Meier survival
curves comparing patients with ≤10% expression of HLA-DRA (gray line) to
patients with >10% expression (black line). The p-values, hazard ratio (HR),
and 95% confidence interval (CI) comparing survival of patients with ≤10
and >10% expression of HLA-DRA are indicated for each cohort. Lenz
CHOP: n= 18≤10% HLA-DRA, n=163> 10% HLA-DRA, Hummel CHOP:
n=10≤10% HLA-DRA, n=92> 10% HLA-DRA, Lenz R-CHOP:
n=23≤10% HLA-DRA, n=210>10% HLA-DRA, Shaknovich R-CHOP:
n=7≤10% HLA-DRA, n= 62>10% HLA-DRA.
mRNA expression in DLBCL specimens from patients in the four
cohorts. All cohorts exhibited variation in HLA-DRA expression
in DLBCL tumors across patients; as in Figure 1A, the relative shift
in expression in the Hummel et al. cohort is due to a difference
in measurement platform. Boxes depict the 10% of patients with
the lowest HLA-DRA expression who were selected to examine the
impact of low HLA-DRA expression on overall survival in DLBCL
(Figure 2A). The closed black symbols in Figure 2A denote the
10% of patients with the lowest GILT expression, demonstrat-
ing that the 10% of patients with the lowest GILT expression are
not the same as the 10% of patients with the lowest HLA-DRA
expression. To further explain this difference, we analyzed the cor-
relation between GILT and HLA-DRA expression. We found that
GILT expression moderately correlated with HLA-DRA expres-
sion in both CHOP cohorts (Lenz CHOP, Spearman ρ= 0.39,
p< 0.0001; Hummel CHOP, Spearman ρ= 0.31, p= 0.0016), and
GILT expression did not correlate with HLA-DRA in either of the
R-CHOP cohorts (Lenz R-CHOP, Spearman ρ= 0.068, p= 0.30;
Shaknovich R-CHOP, Spearman ρ= 0.089, p= 0.47). This is in
contrast to the strong correlation between HLA-DRA expression
and MHC class II-restricted antigen processing pathway members
also regulated by CIITA. The correlation of HLA-DRA expression
with expression of HLA-DRB, HLA-DPA, HLA-DPB, HLA-DQA,
HLA-DQB, HLA-DMA, HLA-DMB, and Ii has previously been
reported with Pearson correlation coefficients between 0.85 and
0.92 (p< 0.001) (27).
Low HLA-DRA expression was significantly associated with
poor survival in the Lenz CHOP group (p= 0.010), but not in
the other three cohorts (Figure 2B). Similarly, a significant two-
times increased hazard of death with low HLA-DRA expression
was identified in the Lenz CHOP cohort, but not the other cohorts
(Figure 2B). This result is consistent with the loss of the associa-
tion between improved survival and the “MHC class II” signature
in the Lenz R-CHOP cohort (23). Together these data show that
while low GILT gene expression is associated with poor survival in
all CHOP and R-CHOP cohorts, low HLA-DRA gene expression
is only associated with poor survival in a single cohort.
GILT EXPRESSION IS NOT ASSOCIATED WITH THE IPI
Patient prognosis in DLBCL is predicted by clinical factors that
comprise the IPI. The IPI ranges from 0 to 5, with each of the
five criteria receiving a point for an unfavorable value. We sought
to determine whether GILT expression is associated with the IPI
score. The IPI score for the Hummel CHOP cohort could not be
determined as patient data for three criteria were not reported. For
the three cohorts examined, there were no statistically significant
differences in the mean GILT expression levels across the IPI scores
(Table 2) (p> 0.65 in each). These data show that GILT expression
is not associated with IPI.
ASSOCIATION OF GILT EXPRESSION WITH SURVIVAL IS INDEPENDENT
OF COO CLASSIFICATION
The COO classification scheme differentiates DLBCL into ABC
and GCB subgroups (21). The ABC subtype correlates with poor
prognosis (21, 22, 42, 43). To determine whether GILT expres-
sion was higher in a particular subgroup, relative GILT expression
was plotted for each patient that was classified into ABC or GCB
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Table 2 | GILT expression is not associated with IPI score.
Mean GILT mRNA expression (SE) p-value
IPI=0 IPI=1 IPI=2 IPI=3 IPI=4 IPI=5
Lenz CHOP 14.37 (0.11) 14.17 (0.09) 14.21 (0.10) 14.13 (0.15) 14.04 (0.18) NA 0.6842
Lenz R-CHOP 14.04 (0.13) 13.96 (0.11) 13.96 (0.13) 13.88 (0.17) 13.69 (0.21) 13.72 (0.42) 0.7752
Shaknovich R-CHOP NA 13.91 (0.18) 13.84 (0.20) 13.84 (0.18) 14.05 (0.24) NA 0.8796
NA indicates not applicable as no patients fit the criteria.
subgroups in Table 1 (Figure 3A). In each cohort, the mean GILT
expression was greater in patients in the GCB subgroup com-
pared to the ABC subgroup. The increase in GILT expression was
statistically significant in the Lenz and Hummel CHOP cohorts
(p= 0.0003 and p= 0.018, respectively). To investigate whether
the impact of GILT expression on survival is independent of COO
classification, we determined the HR comparing ≤10 and >10%
GILT expression adjusting for COO. Low GILT expression con-
ferred a two-times or greater increased risk of death independent
of COO in three cohorts (Lenz CHOP, Lenz R-CHOP, and Sha-
knovich R-CHOP) (Figure 3B). In the fourth cohort, Hummel
CHOP, the HR was no longer statistically significant when adjusted
for COO (Figure 3B). Overall, these data strongly support that
the association of GILT expression with survival in DBLCL is
independent of COO classification.
GILT PROTEIN IS EXPRESSED IN B CELLS AND APCs IN BENIGN
LYMPHOID TISSUE
Although GILT is known to be constitutively expressed in many
APC types including B cells and DCs (3–6), to our knowl-
edge, GILT expression in normal lymphoid organs has not been
reported. We examined GILT protein expression in tonsil by
immunohistochemistry. Figure 4 shows a low power view of stain-
ing with an anti-GILT polyclonal antibody demonstrating GILT
expression within the germinal center, mantle zone, and T cell
zone. Upon higher magnification, GILT staining was observed
within the B cells and follicular DCs of the germinal center, naïve B
cells in the mantle zone, interdigitating DCs in the T cell zone, and
Langerhans cells in the tonsillar epithelium (Figure 4). Consistent
with GILT’s known localization to lysosomes and late endosomes,
GILT staining revealed a punctate intracellular pattern in B cells
and APCs of the tonsil (Figure 4). Of note, GILT staining was not
detected in T cells, epithelial cells, muscle cells, or salivary glands
(Figure 4 and data not shown).
GILT PROTEIN EXPRESSION IN DLBCL
Next, we determined which cell types in DLBCL tumors express
GILT and in which cell type GILT expression varies and thus
may impact tumor biology. We began by evaluating GILT pro-
tein expression in DLBCL cell lines OCI-LY19 (GCB subgroup)
and OCI-LY3 (ABC subgroup) by confocal microscopy. Similar
to immunohistochemistry, confocal microscopy revealed a punc-
tate pattern of GILT staining and a predominantly cell-surface
pattern together with a punctate pattern of MHC class II expres-
sion in DLBCL cell lines (Figure 5A and data not shown). GILT
and MHC class II expression in DLBCL cell lines colocalized in
FIGURE 3 | Association of GILT expression with survival is independent
of COO classification. (A) The relative mRNA expression of GILT in
patients classified as GCB or ABC subtype in the four cohorts. Each symbol
represents an individual patient. Comparison of GILT expression in GCB and
ABC subtypes using a two sample independent t -test revealed p=0.0003
in the Lenz CHOP, p=0.0179 in the Hummel CHOP, p=0.0653 in the Lenz
R-CHOP, and p= 0.2887 in the Shaknovich R-CHOP cohort. The line and
error bars indicate the mean±SEM (*p<0.05). (B) Adjusted for COO
subtype, the hazard ratio, 95% confidence interval and p-value comparing
survival of patients with ≤10 to >10% expression of GILT in each cohort.
the intracellular MHC class II loading compartment (Figure 5A
and data not shown). These findings demonstrated that DLBCL
tumors cells express GILT and that GILT maintains the same
intracellular localization as in benign B cells.
Then, we examined GILT protein expression in 96 DLBCL
tissue specimens in a TMA. A previous study identified GILT
protein expression in tumor-infiltrating DCs in DLBCL, but did
not report GILT expression in tumor cells (26). By using either
a polyclonal antibody (as in Figure 4) or a mAb with sensitive
immunohistochemical techniques including amplification steps
(data not shown), we detected GILT expression in both malignant
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FIGURE 4 | GILT protein is expressed in B cells and APCs in benign
tonsil. GILT expression in normal human tonsil shown with a low power
view (original magnification, ×100) and in the germinal center, mantle zone,
T cell zone, and epithelium (original magnification, ×600). Images were
acquired using a Nikon ECLIPSE 80i microscope with a 10×/0.30 or
60×/0.95 objective lenses, a Nikon DS-Ri1 camera and Nikon NIS-Elements
Imaging software v3.13.
B cells and APCs in DLBCL tumors (Figure 5B). Our results are
supported by GILT expression in DLBCL cell lines OCI-LY3 and
OCI-LY19 (Figure 5A) and are in agreement with other studies
showing GILT is constitutively expressed by primary B cells and
B cell lymphoma lines (3–6). As in the confocal microscopy of
DLBCL cell lines and immunohistochemistry of benign B cells
and other APCs, we observed a punctate pattern of GILT staining
in the malignant B cells (Figure 5B). GILT staining was scored on
a scale from 0 to 4 based on the staining intensity and number
of GILT-expressing vesicles per cell. There was significant vari-
ation in GILT protein expression in malignant B cells reflected
by differences in the tumor intensity score (Figure 5B). Within
DLBCL cells, the range of GILT expression was from 0.5 to 4 with
a mean tumor intensity score of 2.13± 0.8 and a mean frequency
of 69%± 18%. In contrast, GILT expression was uniformly high
in tumor-infiltrating APCs (mean intensity score= 3.65± 0.55,
mean frequency within tumor= 12%± 11%). Even in cases with
low GILT expression in tumor cells, tumor-infiltrating APCs were
strongly positive (Figure 5B). GILT mRNA expression from GEP
studies correlated with the GILT tumor intensity score (Spearman
ρ= 0.53, p< 0.0001) (Figure 5C). There was no statistically sig-
nificant correlation between GILT mRNA and protein expression
in tumor-infiltrating APCs (data not shown). These data defini-
tively demonstrate variation in GILT protein expression in DLBCL
tumor cells which correlates with GILT mRNA expression that is
associated with patient survival.
DISCUSSION
We evaluated the impact of expression of a key enzyme involved in
antigen processing on patient survival in DLBCL. Low GILT gene
expression, which is anticipated to correlate with a lack of GILT
protein function, was significantly associated with poor survival
in four patient cohorts, including patients treated with R-CHOP.
Furthermore, GILT expression was not associated with the clinical
IPI score, and the association of GILT expression with survival was
independent of COO classification. Thus, GILT may relate to an
important independent aspect of tumor biology.
GILT functions in the MHC class II-restricted antigen pro-
cessing pathway by reducing disulfide bonds in the endocytic
compartment to expose buried epitopes for class II-binding. GILT
has been shown to enhance MHC class II-restricted presenta-
tion of multiple epitopes from disulfide bond-containing antigens,
including the model antigen hen egg lysozyme (3), tumor antigens
tyrosinase and tyrosinase-related protein 1 (4, 6), viral glycopro-
teins (7), autoantigen myelin oligodendrocyte glycoprotein (8),
and dust mite allergen Der p 1 (9). Low or absent GILT expression
in MHC class II-expressing melanoma cell lines results in dimin-
ished MHC class II-restricted presentation of endogenous tumor
antigens (6). Furthermore, deficient GILT expression diminishes
CD4+ T cell-mediated responses in in vivo mouse models (3, 4, 9).
In B cell lymphoma lines, manipulations that increase MHC class
II and GILT expression improve CD4+ T cell recognition (44).
Therefore, loss of GILT expression in DLBCL cells is anticipated to
diminish MHC class II-restricted presentation of tumor antigens
and decrease anti-tumor T cell responses.
The association of low GILT expression with survival is stronger
than the association of a classical MHC class II gene with survival.
While the negative consequence of low gene and protein expres-
sion of MHC class II molecules on patient survival in DLBCL
is well-documented, the significance of low HLA-DR expres-
sion on survival has varied between studies and when different
parameters were used (22, 23, 27, 30–32, 39–41). Our data sug-
gest that the quality of antigen processing (i.e., the ability to
generate tumor-specific epitopes) is more critical to patient sur-
vival than the abundance of a particular MHC class II molecule
for antigen presentation. As an upstream member in the MHC
class II-restricted antigen processing and presentation pathway, a
change in GILT expression has the ability to alter the epitopes that
are presented and shape the T cell response. In addition, GILT
expression may be a stronger predictor of survival than any sin-
gle class II gene, because GILT’s reductase activity is anticipated
to improve presentation by HLA-DR, HLA-DP, and HLA-DQ.
Though, in general, expression of these classical class II genes is
tightly correlated (27).
We also examined the impact of expression levels of a gene that
regulates class II trafficking. Membrane-associated RING-CH-1
(MARCH1) is an E3 ubiquitin ligase (45) responsible for target-
ing cell-surface MHC class II and costimulatory CD86 molecules
for degradation (46, 47). Similar to results with HLA-DRA gene
expression, the association of low MARCH1 gene expression with
survival was detected in a single cohort (Lenz CHOP) (data not
shown). Therefore, GILT may be a better individual target for pre-
diction of patient survival than other components of the MHC
class II antigen processing and presentation pathway.
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FIGURE 5 | Variation in GILT protein expression in DLBCL tumor cells
correlates with mRNA expression. (A) In OCI-LY19, a DLBCL GCB
subtype cell line, GILT and HLA-DR expression were detected with Alexa
Fluor 555-conjugated and Alex Flour 488-conjugated secondary antibodies,
respectively. Images were viewed using a Zeiss LSM 710 confocal
microscope with a Plan-APOCHROMAT 63×/1.4 objective lens and
Immersol 518, and acquired with Zen LE software (Carl Zeiss Microimaging
Inc., Thornwood, NY, USA). (B) Low (original magnification, ×200) and high
(Continued)
FIGURE 5 | Continued
power view (original magnification, ×600) of representative GILT staining in
DLBCL patient TMA specimens. Each specimen is labeled with GILT tumor
intensity score, which reflects the intensity of GILT staining and the
number of GILT-expressing vesicles in the malignant B cells (scale from 0 to
4). As a reference, benign tonsillar B cells were scored as 2.0. Images were
acquired using a Nikon ECLIPSE 80i microscope with a 20×/0.50 or
60×/0.95 objective lenses, a Nikon DS-Ri1 camera and Nikon NIS-Elements
Imaging software v3.13. (C) GILT mRNA expression in the tumors from 96
DLBCL patients in GEP studies correlated with GILT protein expression in
the tumor cells (GILT tumor intensity score) (Spearman ρ=0.53,
p<0.0001).
Alternatively, GILT may influence survival through additional
functions outside of antigen processing. For example, GILT has
been shown to alter the cellular redox state, and thus, GILT may
influence survival in DLBCL through alteration of the intracellular
redox environment. Superoxide is metabolized by cytosolic copper,
zinc superoxide dismutase (CuZnSOD or SOD1), mitochondr-
ial manganese SOD (MnSOD or SOD2), and extracellular SOD
(EcSOD or SOD3). GILT-deficient cells have decreased expres-
sion of MnSOD and correspondingly elevated superoxide levels
which may be due to increased autophagy of damaged mitochon-
dria (48–50). GILT does not alter CuZnSOD, and reconstitution
of GILT normalizes MnSOD activity (48, 49). Tome et al. found
that DLBCL patients with the worst survival have alterations in the
expression of genes that regulate the cellular redox environment;
in particular, patients with the poorest survival had significantly
lower MnSOD gene expression and no change in CuZnSOD
expression (51). Thus, GILT’s alteration of cellular redox status
may also contribute to the effect of GILT expression on survival in
DLBCL.
To begin to identify how GILT impacts survival, we identi-
fied the cellular origin of variation in GILT expression in DLBCL
tumors. We found that GILT protein expression varied widely in
the DLBCL cells and that GILT protein expression in tumor cells
correlated with GILT mRNA expression from the GEP studies,
which was associated with patient survival. Only 47 of the DLBCL
tissue specimens were linked with survival data, and this number
does not provide sufficient statistical power to assess the rela-
tionship between GILT protein expression and survival using the
10% cut-off (n= 5≤ 10% GILT expression, n= 42> 10% GILT
expression). However, as a preliminary analysis, when compar-
ing survival using normal GILT protein expression as a cut-off,
there was a statistically significant relationship between low GILT
protein expression and poor survival (n= 30 tumor score≤ 2.0,
n= 17 tumor score> 2.0, log rank test, p= 0.03, data not shown).
Additional studies with a larger cohort are needed to draw a more
definitive conclusion regarding the association of GILT protein
expression with survival. Whereas GILT protein expression var-
ied widely in DLBCL tumor cells, strong GILT protein expression
was relatively conserved in tumor-infiltrating APCs. Furthermore,
GILT expression in tumor-infiltrating APCs did not correlate with
GILT mRNA expression. These results suggest that GILT expres-
sion is altered in tumor cells rather than a germline polymorphism
resulting in low GILT expression in all cell types (52). DLBCL cells
utilize mutations and deletions to inactivate the β2-microglobulin
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gene resulting in loss of MHC class I-restricted presentation (53).
Genomic breaks in the MHC CIITA gene are found in 38% of pri-
mary mediastinal B-cell lymphomas and result in downregulation
of cell-surface MHC class II expression (54). Similarly, loss of GILT
expression in DLBCL cells could represent a novel mechanism of
immune evasion.
In summary, these studies identify a novel association between
low GILT expression and poor survival in patients with DLBCL.
Loss of GILT expression in DLBCL cells may represent a mech-
anism of immune evasion. GILT expression provides additional
information beyond established prognostic indicators. Thus, GILT
merits further attention as a prognostic marker in DBLCL. Over-
all, we propose that antigen processing is a critical pathway in
DLBCL and suggest that molecules targeting this pathway warrant
investigation as potential therapeutics.
AUTHORS CONTRIBUTION
Karen Taraszka Hastings designed the research. Hannah Phipps-
Yonas and Ellen Haddock performed the research. Karen Taraszka
Hastings and Hannah Phipps-Yonas analyzed and interpreted the
data. Denise J. Roe and Haiyan Cui performed the statistical
analysis. Noemi Sebastiao performed and Patrick S. Brunhoe-
ber scored the immunohistochemical staining. Martin J. Deymier
and Lonnie Lybarger performed the MARCH1 analysis. Wolfram
Klapper provided the TMAs. Karen Taraszka Hastings wrote the
manuscript along with contributions from Hannah Phipps-Yonas,
Noemi Sebastiao, Patrick S. Brunhoeber, Ellen Haddock, Lonnie
Lybarger, and Denise J. Roe. All authors reviewed and approved
the final manuscript.
ACKNOWLEDGMENTS
The authors thank the Molecular Mechanisms of Malignant Lym-
phoma Network for providing DLBCL tissue specimens; Dr. Lisa
Rimsza for her assistance with study design and review of GILT
staining in tonsil; and Dr. Tom Grogan, Alisa Tubbs and the
Immune Profiling Team at Ventana Medical Systems, Inc. for
technical assistance with immunohistochemistry. This work was
supported in part by National Institutes of Health grants K08-
AR054388 (Karen Taraszka Hastings), T32-CA009213 (Hannah
Phipps-Yonas), R56-AI080756 (Lonnie Lybarger), and Arizona
Cancer Center Core Support Grant P30-CA023074 (Haiyan Cui,
Denise J. Roe) and a grant from the Arizona Biomedical Research
Commission (Karen Taraszka Hastings).
REFERENCES
1. van den Hoorn T, Paul P, Jongsma ML, Neefjes J. Routes to manipulate
MHC class II antigen presentation. Curr Opin Immunol (2011) 23(1):88–95.
doi:10.1016/j.coi.2010.11.002
2. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell (2002)
109(Suppl):S21–33. doi:10.1016/S0092-8674(02)00696-7
3. Maric M, Arunachalam B, Phan UT, Dong C, Garrett WS, Cannon
KS, et al. Defective antigen processing in GILT-free mice. Science (2001)
294(5545):1361–5. doi:10.1126/science.1065500
4. Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT. GILT
accelerates autoimmunity to the melanoma antigen tyrosinase-related protein
1. J Immunol (2010) 185(5):2828–35. doi:10.4049/jimmunol.1000945
5. Hastings KT, Lackman RL, Cresswell P. Functional requirements for the lyso-
somal thiol reductase GILT in MHC class II-restricted antigen processing.
J Immunol (2006) 177(12):8569–77.
6. Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW, Phan UT, et al. Absence
of gamma-interferon-inducible lysosomal thiol reductase in melanomas dis-
rupts T cell recognition of select immunodominant epitopes. J Exp Med (2002)
195(10):1267–77. doi:10.1084/jem.20011853
7. Sealy R, Chaka W, Surman S, Brown SA, Cresswell P, Hurwitz JL. Target pep-
tide sequence within infectious human immunodeficiency virus type 1 does
not ensure envelope-specific T-helper cell reactivation: influences of cysteine
protease and gamma interferon-induced thiol reductase activities. Clin Vaccine
Immunol (2008) 15(4):713–9. doi:10.1128/CVI.00412-07
8. Bergman CM, Marta CB, Maric M, Pfeiffer SE, Cresswell P, Ruddle NH. A switch
in pathogenic mechanism in myelin oligodendrocyte glycoprotein-induced
experimental autoimmune encephalomyelitis in IFN-gamma-inducible lysoso-
mal thiol reductase-free mice. J Immunol (2012) 188(12):6001–9. doi:10.4049/
jimmunol.1101898
9. West LC, Grotzke JE, Cresswell P. MHC class II-restricted presentation of the
major house dust mite allergen Der p 1 Is GILT-dependent: implications for aller-
gic asthma. PLoS One (2013) 8(1):e51343. doi:10.1371/journal.pone.0051343
10. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger
SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T
lymphocytes. Nature (2003) 421(6925):852–6. doi:10.1038/nature01441
11. Antony PA, Piccirillo CA,Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al.
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T
helper cells and hindered by naturally occurring T regulatory cells. J Immunol
(2005) 174(5):2591–601.
12. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are
required for secondary expansion of CD8+ memory T cells. Nature (2006)
441(7095):890–3. doi:10.1038/nature04790 Epub 2006/06/17.
13. Jo YS, Lee JC, Li S, Choi YS, Bai YS, Kim YJ, et al. Significance of the expres-
sion of major histocompatibility complex class II antigen, HLA-DR and -DQ,
with recurrence of papillary thyroid cancer. Int J Cancer (2008) 122(4):785–90.
doi:10.1002/ijc.23167
14. Oldford SA, Robb JD, Watson PH, Drover S. HLA-DRB alleles are differ-
entially expressed by tumor cells in breast carcinoma. Int J Cancer (2004)
112(3):399–406. doi:10.1002/ijc.20441
15. Warabi M, Kitagawa M, Hirokawa K. Loss of MHC class II expression is associ-
ated with a decrease of tumor-infiltrating T cells and an increase of metastatic
potential of colorectal cancer: immunohistological and histopathological analy-
ses as compared with normal colonic mucosa and adenomas. Pathol Res Pract
(2000) 196(12):807–15. doi:10.1016/S0344-0338(00)80080-1
16. Zehbe I, Hohn H, Pilch H, Neukirch C, Freitag K, Maeurer MJ. Differen-
tial MHC class II component expression in HPV-positive cervical cancer
cells: implication for immune surveillance. Int J Cancer (2005) 117(5):807–15.
doi:10.1002/ijc.21226
17. A clinical evaluation of the International Lymphoma Study Group classifica-
tion of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification
project. Blood (1997) 89(11):3909–18.
18. A predictive model for aggressive non-Hodgkin’s lymphoma. The International
non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med (1993)
329(14):987–94. doi:10.1056/NEJM199309303291402
19. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Intro-
duction of combined CHOP plus rituximab therapy dramatically improved
outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol
(2005) 23(22):5027–33. doi:10.1200/JCO.2005.09.137
20. Coiffier B, Thieblemont C, van den Neste E, Lepeu G, Plantier I, Castaigne S,
et al. Long-term outcome of patients in the LNH-98.5 trial, the first random-
ized study comparing rituximab-CHOP to standard CHOP chemotherapy in
DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte.
Blood (2010) 116(12):2040–5. doi:10.1182/blood-2010-03-276246
21. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct
types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature (2000) 403(6769):503–11. doi:10.1038/35000501
22. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The
use of molecular profiling to predict survival after chemotherapy for diffuse
large-B-cell lymphoma. N Engl J Med (2002) 346(25):1937–47. doi:10.1056/
NEJMoa012914
23. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene
signatures in large-B-cell lymphomas. N Engl J Med (2008) 359(22):2313–23.
doi:10.1056/NEJMoa0802885
www.frontiersin.org December 2013 | Volume 4 | Article 425 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phipps-Yonas et al. GILT correlates with DLBCL survival
24. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A
biologic definition of Burkitt’s lymphoma from transcriptional and genomic
profiling. N Engl J Med (2006) 354(23):2419–30. doi:10.1056/NEJMoa055351
25. Shipp MA, Ross KN, Tamayo P,Weng AP, Kutok JL,Aguiar RC, et al. Diffuse large
B-cell lymphoma outcome prediction by gene-expression profiling and super-
vised machine learning. Nat Med (2002) 8(1):68–74. doi:10.1038/nm0102-68
26. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular
profiling of diffuse large B-cell lymphoma identifies robust subtypes including
one characterized by host inflammatory response. Blood (2005) 105(5):1851–61.
doi:10.1182/blood-2004-07-2947
27. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, et al. Loss
of MHC class II gene and protein expression in diffuse large B-cell lymphoma
is related to decreased tumor immunosurveillance and poor patient survival
regardless of other prognostic factors: a follow-up study from the Leukemia
and Lymphoma Molecular Profiling Project. Blood (2004) 103(11):4251–8.
doi:10.1182/blood-2003-07-2365
28. Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, et al. Predic-
tion of survival in diffuse large B-cell lymphoma based on the expression of
2 genes reflecting tumor and microenvironment. Blood (2011) 118(5):1350–8.
doi:10.1182/blood-2011-03-345272
29. Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, et al.
DNA methylation signatures define molecular subtypes of diffuse large B-cell
lymphoma. Blood (2010) 116(20):e81–9. doi:10.1182/blood-2010-05-285320
30. Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, et al.
Loss of HLA-DR expression and immunoblastic morphology predict adverse
outcome in diffuse large B-cell lymphoma – analyses of cases from two
prospective randomized clinical trials. Haematologica (2009) 94(11):1569–80.
doi:10.3324/haematol.2009.008862
31. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al.
Gene expression predicts overall survival in paraffin-embedded tissues of dif-
fuse large B-cell lymphoma treated with R-CHOP. Blood (2008) 112(8):3425–33.
doi:10.1182/blood-2008-02-137372
32. Rimsza LM, Unger JM, Tome ME, Leblanc ML. A strategy for full interrogation of
prognostic gene expression patterns: exploring the biology of diffuse large B cell
lymphoma. PLoS One (2011) 6(8):e22267. doi:10.1371/journal.pone.0022267
33. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is
sufficient for the inducible expression of major histocompatibility complex class
II genes. J Exp Med (1994) 180(4):1367–74. doi:10.1084/jem.180.4.1367
34. Chin KC, Mao C, Skinner C, Riley JL, Wright KL, Moreno CS, et al. Molecular
analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or
RFX result in defective class II MHC and Ii gene induction. Immunity (1994)
1(8):687–97. doi:10.1016/1074-7613(94)90039-6
35. O’Donnell PW, Haque A, Klemsz MJ, Kaplan MH, Blum JS. Cutting edge:
induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal
thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent.
J Immunol (2004) 173(2):731–5.
36. Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaver-
ria I, et al. Patient age at diagnosis is associated with the molecular char-
acteristics of diffuse large B-cell lymphoma. Blood (2012) 119(8):1882–7.
doi:10.1182/blood-2011-10-388470
37. Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al.
Translocations activating IRF4 identify a subtype of germinal center-derived B-
cell lymphoma affecting predominantly children and young adults. Blood (2011)
118(1):139–47. doi:10.1182/blood-2011-01-330795
38. Tweeddale ME, Lim B, Jamal N, Robinson J, Zalcberg J, Lockwood G, et al. The
presence of clonogenic cells in high-grade malignant lymphoma: a prognostic
factor. Blood (1987) 69(5):1307–14.
39. Miller TP, Lippman SM, Spier CM, Slymen DJ, Grogan TM. HLA-DR (Ia)
immune phenotype predicts outcome for patients with diffuse large cell lym-
phoma. J Clin Invest (1988) 82(1):370–2. doi:10.1172/JCI113598
40. Rimsza LM, Farinha P, Fuchs DA, Masoudi H, Connors JM, Gascoyne RD.
HLA-DR protein status predicts survival in patients with diffuse large B-cell
lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma
(2007) 48(3):542–6. doi:10.1080/10428190601078605
41. Spier CM, Grogan TM, Lippman SM, Slymen DJ, Rybski JA, Miller TP. The aber-
rancy of immunophenotype and immunoglobulin status as indicators of prog-
nosis in B cell diffuse large cell lymphoma. Am J Pathol (1988) 133(1):118–26.
42. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kap-
paB activity is required for survival of activated B cell-like diffuse large B cell lym-
phoma cells. J Exp Med (2001) 194(12):1861–74. doi:10.1084/jem.194.12.1861
43. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al.
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large
B-cell lymphoma. Nature (2009) 459(7247):717–21. doi:10.1038/nature07968
44. Radwan FF, Zhang L, Hossain A, Doonan BP, God JM, Haque A. Mechanisms
regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell
recognition of human B-cell lymphoma by resveratrol. Leuk Lymphoma (2012)
53(2):305–14. doi:10.3109/10428194.2011.615423
45. Bartee E, Mansouri M, Hovey Nerenberg BT, Gouveia K, Fruh K. Downreg-
ulation of major histocompatibility complex class I by human ubiquitin lig-
ases related to viral immune evasion proteins. J Virol (2004) 78(3):1109–20.
doi:10.1128/JVI.78.3.1109-1120.2004
46. Matsuki Y, Ohmura-Hoshino M, Goto E, Aoki M, Mito-Yoshida M, Uematsu
M, et al. Novel regulation of MHC class II function in B cells. EMBO J (2007)
26(3):846–54. doi:10.1038/sj.emboj.7601556
47. De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, et al.
MHC class II stabilization at the surface of human dendritic cells is the result
of maturation-dependent MARCH I down-regulation. Proc Natl Acad Sci U S A
(2008) 105(9):3491–6. doi:10.1073/pnas.0708874105
48. Maric M, Barjaktarevic I, Bogunovic B, Stojakovic M, Maric C, Vukmanovic
S. Cutting edge: developmental up-regulation of IFN-gamma-inducible lysoso-
mal thiol reductase expression leads to reduced T cell sensitivity and less severe
autoimmunity. J Immunol (2009) 182(2):746–50.
49. Bogunovic B, Stojakovic M, Chen L, Maric M. An unexpected functional link
between lysosomal thiol reductase and mitochondrial manganese superoxide
dismutase. J Biol Chem (2008) 283(14):8855–62. doi:10.1074/jbc.M708998200
50. Chiang HS, Maric M. Lysosomal thiol reductase negatively regulates autophagy
by altering glutathione synthesis and oxidation. Free Radic Biol Med (2011)
51(3):688–99. doi:10.1016/j.freeradbiomed.2011.05.015
51. Tome ME, Johnson DB, Rimsza LM, Roberts RA, Grogan TM, Miller TP, et al.
A redox signature score identifies diffuse large B-cell lymphoma patients with a
poor prognosis. Blood (2005) 106(10):3594–601. doi:10.1182/blood-2005-02-
0487
52. Turcot V, Bouchard L, Faucher G, Tchernof A, Deshaies Y, Perusse L, et al. A poly-
morphism of the interferon-gamma-inducible protein 30 gene is associated with
hyperglycemia in severely obese individuals. Hum Genet (2012) 131(1):57–66.
doi:10.1007/s00439-011-1043-4
53. Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, et al.
Combined genetic inactivation of beta2-microglobulin and CD58 reveals fre-
quent escape from immune recognition in diffuse large B cell lymphoma. Cancer
Cell (2011) 20(6):728–40. doi:10.1016/j.ccr.2011.11.006
54. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class
II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Nature (2011) 471(7338):377–81. doi:10.1038/nature09754
Conflict of Interest Statement: Noemi Sebastiao and Patrick S. Brunhoeber are
employees of Ventana Medical Systems who contributed to this study as part of a
collaborative research agreement with no payment to either Ventana or academic
investigators. The remaining authors declare no competing financial interest.
Received: 29 August 2013; accepted: 20 November 2013; published online: 04 December
2013.
Citation: Phipps-Yonas H, Cui H, Sebastiao N, Brunhoeber PS, Haddock E, Deymier
MJ, Klapper W, Lybarger L, Roe DJ and Hastings KT (2013) Low GILT expression is
associated with poor patient survival in diffuse large B-cell lymphoma. Front. Immunol.
4:425. doi: 10.3389/fimmu.2013.00425
This article was submitted to Antigen Presenting Cell Biology, a section of the journal
Frontiers in Immunology.
Copyright © 2013 Phipps-Yonas, Cui, Sebastiao, Brunhoeber, Haddock, Deymier,
Klapper, Lybarger , Roe and Hastings. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Immunology | Antigen Presenting Cell Biology December 2013 | Volume 4 | Article 425 | 10
